Peter Attia· MD
so while we do have an outcome trial ongoing right now in person who were overweight and obese but without diabetes with the glp-1 receptor agonists I'm anticipating this will also be beneficial for cardiovascular disease
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so while we do have an outcome trial ongoing right now in person who were overweight and obese but without diabetes with the glp-1 receptor agonists I'm anticipating this will also be beneficial for cardiovascular disease
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
at least now we do have some new pharmacological agents that are beneficial in weight loss that do not have cardiovascular harm like some of the older weight loss drugs and may actually be cardiovascularly beneficial we know the glp-1 receptor agonists at least in patients with type 2 diabetes you know reduces the risk of major adverse cardiovascular events and stroke